Discontinued — last reported Q4 '17
Indefinite-Lived Research and Development Assets
Merck & Co. Indefinite-Lived Research and Development Assets increased by 35.0% to $4.13B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 35.0%, from $3.06B to $4.13B. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 97.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates active investment in future technology, while a decrease may signal project completion or impairment.
Detailed definition
These are acquired in-process research and development (IPR&D) projects that have not yet reached technological feasibil...
Peer comparison
Common in technology and pharmaceutical sectors following M&A activity.
indefinite_lived_rd_assetsHistorical Data
| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $274.00M | $1.34B | $2.10B | $3.06B | $4.13B |
| QoQ Change | — | +389.4% | +56.5% | +45.9% | +35.0% |
| YoY Change | — | +389.4% | +56.5% | +45.9% | +35.0% |
Product Breakdown
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s indefinite-lived research and development assets?
- Merck & Co. (MRK) reported indefinite-lived research and development assets of $4.13B in Q4 2025.
- How has Merck & Co.'s indefinite-lived research and development assets changed year-over-year?
- Merck & Co.'s indefinite-lived research and development assets increased by 35.0% year-over-year, from $3.06B to $4.13B.
- What is the long-term trend for Merck & Co.'s indefinite-lived research and development assets?
- Over 4 years (2021 to 2025), Merck & Co.'s indefinite-lived research and development assets has grown at a 97.1% compound annual growth rate (CAGR), from $274.00M to $4.13B.
- What does indefinite-lived research and development assets mean?
- The value of research projects acquired from other companies that are still in progress.